Grace Therapeutics, Inc.
GRCE
$2.95
-$0.05-1.67%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.51M | 1.86M | 2.26M | 1.58M | 1.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.70M | 4.83M | 4.96M | 3.21M | 3.04M |
| Operating Income | -3.70M | -4.83M | -4.96M | -3.21M | -3.04M |
| Income Before Tax | -4.76M | -4.28M | -3.34M | -4.06M | -2.60M |
| Income Tax Expenses | -605.00K | -852.00K | -724.00K | -889.00K | -208.00K |
| Earnings from Continuing Operations | -4.16M | -3.43M | -2.62M | -3.17M | -2.39M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.16M | -3.43M | -2.62M | -3.17M | -2.39M |
| EBIT | -3.70M | -4.83M | -4.96M | -3.21M | -3.04M |
| EBITDA | -3.70M | -4.83M | -4.96M | -3.20M | -3.04M |
| EPS Basic | -0.36 | -0.30 | -0.24 | -0.28 | -0.21 |
| Normalized Basic EPS | -0.26 | -0.23 | -0.19 | -0.22 | -0.14 |
| EPS Diluted | -0.36 | -0.30 | -0.24 | -0.28 | -0.21 |
| Normalized Diluted EPS | -0.26 | -0.23 | -0.19 | -0.22 | -0.14 |
| Average Basic Shares Outstanding | 11.51M | 11.51M | 10.93M | 11.49M | 11.51M |
| Average Diluted Shares Outstanding | 11.51M | 11.51M | 10.93M | 11.49M | 11.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |